Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Zentalis Pharmaceuticals, Inc. ZNTL

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
22.92
Total sells
10.11
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — 1 — — — — — — — 1 —
Sell — — 1 — 4 — — — — — — —
Insider Ownership
5.92%

Capital & Financial Ratios

Market Cap
291.59
Revenue
—
Net Income
(139.54)
Free Cash Flow
(128.00)
Net Debt
(174.61)
Current Ratio
4.82
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
1.54
Past 5Y EPS Growth
(12.89%)
This Y EPS Growth
(11.47%)
Next Y EPS Growth
8.30%
Next 5Y EPS Growth
2.77%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 482.92 371.08 245.89 174.61
Receivables — 5.00 — —
Inventory — — — —
Other — — — —
496.72 386.07 253.19 181.28
2023 2024 2025 Q'26
Payables 14.93 7.44 7.21 8.14
ST’ Debt — — — —
Other — — — —
69.37 52.73 36.56 37.63
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’24 40.56 — — 26.87
67.43
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (32.96) (37.24) — —
—
’25 (32.64) (34.71) (26.96) (30.94)
(125.25)
’24 (51.97) (35.14) (44.04) (39.70)
(170.86)
’23 (49.28) (79.27) (38.66) (40.60)
(207.82)
’22 (50.20) (43.03) (33.20) (37.33)
(163.75)
’21 (37.47) (46.11) (33.49) (37.02)
(154.09)
’20 (16.87) (22.03) (20.56) (27.36)
(86.82)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (32.99) (37.24) — —
—
’25 (32.63) (34.14) (26.96) (30.81)
(124.55)
’24 (52.01) (35.25) (44.04) (39.70)
(171.02)
’23 (49.28) (79.59) (38.76) (40.77)
(208.40)
’22 (50.65) (43.30) (34.86) (37.49)
(166.30)
’21 (37.90) (46.93) (36.15) (39.21)
(160.20)
’20 (16.90) (22.06) (20.60) (28.02)
(87.58)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.50) (0.59) — —
—
’25 (0.67) (0.37) (0.37) (0.49)
(1.91)
’24 0.14 (1.24) (0.56) (0.66)
(2.33)
’23 (1.07) (1.85) (0.79) (0.83)
(4.47)
’22 (1.31) (1.34) (0.96) (0.92)
(4.48)
’21 (1.24) (1.34) (0.09) (1.11)
(3.72)
’20 (2.88) (0.78) (0.91) (1.01)
(4.19)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡ ‡‡‡‡‡ 17.33 9.56 2.66 1.01 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 84.14 31.46 18.07 3.33 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 156 168 166 106 — — —
Employees
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.41 0.00 — — —
Revenue/Emp
— — ‡‡‡‡‡ — — — — — 67.43 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — 100.00% — — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (221.30) (276.89) (165.69) (136.62) — — —
EBT
— — ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% (245.74%) 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (237.11) (292.30) (165.87) (137.06) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.30) (11.77) (2.98) (2.02) — — —
Depreciation
— — ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.95 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.48) (4.47) (2.33) (1.91) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.10) (3.18) (2.40) (1.74) — — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.05) (0.01) 0.00 0.01 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.15) (3.19) (2.41) (1.73) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.21 6.69 4.74 3.01 ‡‡‡‡ — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.86 65.41 71.08 71.87 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡ — — — — — 0.00 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — ‡‡‡ — — — — — 0.00 — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡ — — — — — 0.64 — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡ — — — — — 0.00 — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ — — — — — 0.64 — — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (163.75) (207.82) (170.86) (125.25) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.55) (0.58) (0.16) 0.70 ‡‡‡‡‡ — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (166.30) (208.40) (171.02) (124.55) ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 395.29 427.35 333.34 216.63 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 47.33 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (390.04) (482.92) (371.08) (245.89) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 434.02 437.39 337.19 216.20 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.66%) (53.56%) (33.77%) (38.11%) — — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (322.99%) 0.00% 0.00% 0.00% — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (59.31%) (67.06%) (42.82%) (49.53%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Zentalis Pharmaceuticals (ZNTL), a clinical-stage oncology biotech, has endured wild volatility since its 2020 IPO, soaring to 3,500% premiums in 2021 on pipeline hype before crashing amid trial setbacks like azenosertib failures and a biotech funding drought. Trading at depressed multiples with nascent revenue from partnerships and a 1.9-year cash runway, the stock now sits at attractive 0.64x PB ratios, but persistent losses and projections of cratering revenue to $16M through 2027 underscore high binary risks in this sentiment-driven sector.

Insider signals are mixed—net selling but anchored by massive buys at lows—while analysts forecast 88% mean upside (high 318%), pricing in 20% odds of pipeline wins like 2026 azenosertib Phase 2b data, which could spark 50-100% moves per historical precedents. Fundamentals show improving ROA and non-dilutive cash infusions, positioning ZNTL in the top quartile of peers for turnaround potential amid oncology M&A resurgence.

Yet, with 70% dilution risk in cash-strapped biotechs and brutal Phase 2 attrition (only 20% succeed), ZNTL remains a high-conviction lottery ticket: undervalued cash buffer meets looming catalysts, urging small positions for statistical edges in this volatile space.

Read full commentary →

Zentalis Pharmaceuticals, Inc. (ZNTL) Latest News

News by impact score

Fine-tune

13 Aug

3 , 10:23 PM
Zentalis Pharmaceuticals, Inc. (ZNTL) priced an underwritten public offering of its common stock. Public offering raises capital for operations while diluting shares and likely pressuring near-term stock price.

3 , 4:01 PM
Zentalis Pharmaceuticals announced a proposed underwritten public offering of common stock to raise capital. Public offering raises fresh capital for operations but dilutes shareholders and often pressures stock price short term.

6 Aug

4 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals, Inc. (ZNTL) reported its financial results for the second quarter of 2025, highlighting operational progress and advancements in its clinical pipeline. The company continues to focus on developing innovative therapies for cancer treatment, with updates on ongoing trials and collaborations. Financial metrics indicate growth, with increased revenue and reduced losses compared to previous quarters, reflecting the company's strategic initiatives and market positioning. Significant advancements in clinical trials and financial growth indicate a strong potential for future performance.

3 , 4:05 PM
Zentalis Pharmaceuticals reported second quarter 2026 financial results and business updates. Quarterly financial results and business updates directly affect valuation metrics and short-term market perception.

21 May

4 GlobeNewswire, 5:39 PM
Zentalis Pharmaceuticals will present Phase 1b MUIR trial data at ASCO 2026 showing encouraging clinical activity and manageable safety for Azenosertib plus Paclitaxel in platinum-resistant ovarian cancer. Positive Phase 1b data presentation at ASCO 2026 for lead asset Azenosertib is likely to lift investor sentiment and advance Zentalis pipeline prospects.

12 May

3 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals reported first quarter 2026 financial results, including cash position, R&D expenses, and G&A costs, alongside clinical progress updates on azenosertib, ZH9N, and pipeline advancements. Quarterly financial results with clinical pipeline updates moderately influence biotech investor sentiment and near-term performance.

5 May

4 GlobeNewswire, 8:00 AM
Zentalis Pharmaceuticals dosed the first patient in the ASPENOVA Phase 3 trial of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. Dosing first patient in Phase 3 trial advances key oncology asset toward regulatory approval, boosting pipeline value and investor sentiment.

21 Apr

3 , 10:27 AM
Zentalis Pharmaceuticals announces abstract acceptance at ASCO 2026 featuring azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer. ASCO abstract acceptance validates azenosertib's potential in ovarian cancer combo therapy, moderately enhancing pipeline credibility and investor sentiment.

20 Apr

4 , 10:47 AM
Zentalis Pharmaceuticals (ZNTL) finalized the recommended Phase 2 dose for its cancer drug azenosertib following positive data, prompting Jefferies to raise its price target to $55 from $45 while maintaining a Buy rating. Locking in the cancer drug dose advances clinical trials significantly, with Jefferies' raised price target signaling strong analyst optimism for ZNTL's trajectory.

12 Apr

4 Simply Wall St., 10:11 PM
Zentalis Pharmaceuticals (ZNTL) achieves dose selection milestone for Azenosertib, prompting valuation analysis highlighting potential upside from clinical progress in ovarian and other cancers. Azenosertib dose selection de-risks a lead pipeline candidate, advancing ZNTL toward pivotal trials and significantly enhancing valuation prospects.

9 Apr

4 GlobeNewswire, 8:00 AM
Zentalis Pharmaceuticals announces 400mg QD 5:2 azenosertib monotherapy as the pivotal study dose in Cyclin E1-positive platinum-resistant ovarian cancer. Advancing azenosertib to pivotal study dose in ovarian cancer represents a major clinical milestone that could significantly boost Zentalis' pipeline value and investor sentiment.

26 Mar

4 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals reported full year 2025 financial results and provided operational updates on its clinical pipeline and business progress. Full year financial results and operational updates reveal key financial health and pipeline advancements that significantly impact investor sentiment and stock trajectory.

4 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals reported positive clinical data for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer, with plans to advance to DENALI Part 2 by mid-2025 and disclose topline data by the end of 2026. The company has a cash balance of $371.1 million, projected to last into late 2027. R&D expenses decreased to $167.8 million, while G&A expenses rose to $87.1 million. Zentalis received Fast Track Designation from the FDA for azenosertib and strengthened its management team to support its focused strategy. The advancements in clinical trials and FDA Fast Track Designation are significant strategic moves that could greatly influence Zentalis's future performance and market sentiment.

16 Feb

4 www.marketbeat.com, 5:09 AM
Zentalis Pharmaceuticals outlines the regulatory path for Azenosertib toward PROC approval and anticipates announcing the DENALI trial dose selection soon. Azenosertib's defined path to PROC approval and imminent DENALI dose selection mark critical clinical and regulatory milestones boosting ZNTL's prospects.

11 Jan

4 Simply Wall St., 5:08 PM
Zentalis Pharmaceuticals, Inc. is experiencing positive developments with its drug Azenosertib, which has shown promising results in clinical trials. Insider buying activity suggests confidence in the company's future prospects. Analysts are evaluating the company's valuation in light of these advancements and the potential market impact of Azenosertib. The combination of clinical progress and insider investment may influence investor sentiment and market performance moving forward. The progress of Azenosertib and insider buying indicate significant potential for future growth and market confidence.

8 Jan

3 Simply Wall St., 7:27 AM
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) experienced a 13% decline over the past year, but recent gains have brought some relief to its institutional owners. The company's stock performance has been closely monitored, and the recent uptick may signal a positive shift in investor sentiment. Recent gains may influence market sentiment and financial performance, but the overall effect is expected to be limited.

6 Jan

4 GlobeNewswire, 8:00 AM
Zentalis Pharmaceuticals, Inc. provided a corporate update highlighting key milestones and anticipated momentum in the development program for Azenosertib, with plans for significant advancements in 2026. The company outlined its strategic focus on enhancing clinical trials and expanding its pipeline, aiming to strengthen its market position and investor confidence. The anticipated advancements in the Azenosertib development program are likely to significantly impact the company's future performance and market positioning.

3 Dec

3 Simply Wall St., 8:01 AM
Zentalis Pharmaceuticals is under scrutiny for its cash burn rate as it navigates its financial landscape. Investors are concerned about the sustainability of its operations given the current cash reserves and ongoing expenditures. The company is focusing on its pipeline and potential revenue streams to mitigate risks associated with its cash flow. Analysts are closely monitoring these developments to assess the impact on Zentalis' future performance. The cash burn rate could moderately influence Zentalis' financial performance and investor sentiment.

10 Nov

3 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, highlighting operational progress and advancements in its clinical pipeline. The company continues to focus on developing innovative therapies for cancer treatment, with updates on ongoing trials and collaborations. Financial metrics indicate a stable position, with investments aimed at enhancing research and development efforts. Ongoing clinical developments and financial stability may moderately influence Zentalis's market position and investor sentiment.

13 Oct

3 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals, Inc. announced the presentation of four posters on Azenosertib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. These presentations highlight the ongoing research and development efforts surrounding Azenosertib, a drug candidate aimed at treating various cancers. The conference serves as a platform for sharing significant advancements in cancer therapeutics, potentially enhancing Zentalis's visibility and engagement within the oncology community. The poster presentations may enhance Zentalis's reputation and contribute to future research collaborations, but the immediate financial impact is expected to be limited.

6 Oct

3 Simply Wall St., 11:39 AM
Insider buying activity at Zentalis Pharmaceuticals, Inc. has been noted, with several executives purchasing shares of the company's stock. This trend is often viewed positively by investors, as it may indicate confidence in the company's future prospects. The increased insider ownership could signal a belief in the potential success of Zentalis' ongoing projects and overall business strategy. Insider purchases can indicate confidence in the company's future, potentially influencing market sentiment and stock performance.

26 Aug

3 , 4:05 PM
Zentalis Pharmaceuticals, Inc. has appointed James B. Bucher, JD, as the new Chief Legal Officer and Corporate Secretary. Bucher brings extensive legal experience in the pharmaceutical and biotechnology sectors, having previously held senior legal positions at various companies. His appointment is expected to enhance Zentalis' legal and corporate governance capabilities as the company continues to advance its pipeline of cancer therapies. The appointment of a new Chief Legal Officer may moderately influence the company's operations and governance, impacting its strategic direction.

23 Jul

3 , 12:34 PM
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has garnered significant support from institutional investors, who collectively own 59% of the company. This level of institutional ownership may indicate confidence in Zentalis's future prospects and stability in the market. Institutional ownership at 59% suggests a moderately noticeable influence on market sentiment and potential stability for Zentalis.

26 Jun

3 , 8:04 AM
Zentalis Pharmaceuticals is facing scrutiny over its cash burn rate as it navigates the challenges of funding its clinical trials and operations. Investors are concerned about the sustainability of its financial resources, especially in light of the competitive landscape in the biotech sector. The company's ability to manage its cash flow effectively will be crucial for its future growth and development of its drug pipeline. The cash burn situation may moderately influence Zentalis' financial performance and investor sentiment, but it is not expected to drastically alter its overall trajectory.

16 May

3 , 6:08 AM
Zentalis Pharmaceuticals, Inc. reported a loss of $0.67 per share for the first quarter of 2025, a significant decline from a profit of $0.14 per share in the same quarter of 2024. This marks a notable shift in the company's financial performance, raising concerns among investors. The substantial loss per share indicates potential challenges in financial performance that could affect investor sentiment.

14 May

4 GlobeNewswire, 4:05 PM
Zentalis Pharmaceuticals reported its first quarter 2025 financial results, highlighting the dosing of the first patient in the DENALI Part 2a clinical trial of azenosertib for Cyclin E1+ platinum-resistant ovarian cancer. The company anticipates topline data by the end of 2026, which could support accelerated approval. Zentalis has $332.5 million in cash and equivalents, sufficient to fund operations into late 2027. Research and development expenses decreased to $27.2 million, while general and administrative expenses fell to $10.6 million. The company plans to participate in several upcoming conferences and events. The initiation of late-stage clinical trials and potential for accelerated approval could significantly impact Zentalis's market position and investor sentiment.

29 Apr

3 Simply Wall St., 11:00 AM
Several insiders at Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have recently purchased shares, indicating confidence in the company's future. Over the past year, insiders bought $223k worth of shares while selling $108k, suggesting a net positive sentiment. The largest purchase was made by Independent Director Jan Skvarka, who bought $103k worth of shares at $1.72 each, above the current price of $1.42. Insiders own about 2.8% of the company, valued at $2.9m, which is considered low. Despite the positive insider transactions, the company is facing losses and has two warning signs that investors should be aware of. Insider buying suggests optimism, but ongoing losses and low insider ownership limit the overall impact.

28 Apr

4 GlobeNewswire, 8:00 AM
Zentalis Pharmaceuticals, Inc. has announced the dosing of the first patient in the DENALI Part 2 clinical trial for Azenosertib, targeting patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). This trial aims to evaluate the efficacy and safety of Azenosertib in this specific patient population, building on previous findings that suggest potential benefits in treating PROC. The initiation of a significant clinical trial for a targeted therapy in a specific cancer type could substantially influence Zentalis's market position and investor sentiment.

23 Apr

4 , 4:05 PM
Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for poster presentation at the 2025 ASCO Annual Meeting, showcasing clinical data from its Phase 1/2 trial of azenosertib in combination with encorafenib and cetuximab for metastatic BRAF V600E mutant colorectal cancer. The presentation is scheduled for May 31, 2025, in Chicago, IL. Azenosertib is a WEE1 inhibitor being evaluated for various tumor types, including ovarian cancer. The acceptance of the abstract for a major oncology conference indicates significant progress in clinical development that could enhance investor sentiment and market positioning.

25 Mar

4 GlobeNewswire, 4:40 PM
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced four poster presentations at the 2025 AACR Annual Meeting, showcasing the potential of azenosertib, a WEE1 inhibitor, in treating high-grade serous ovarian cancer and other tumor types. One poster will focus on cell-free DNA molecular response as a surrogate endpoint for clinical efficacy, while others will highlight azenosertib's broad therapeutic applications as both a single agent and in combination therapies. The meeting will take place from April 25-30, 2025, in Chicago, IL. The presentations at a major cancer research conference could significantly influence investor sentiment and the company's strategic positioning in the oncology market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us